HCW Biologics Inc. (HCWB) Form 8-K — Aug 14, 2026
HCW Biologics (Nasdaq: HCWB) reported Q2 2026 results on August 14, 2026, with revenue of $135,568 for the quarter and $6.7 million for the first six months, driven mainly by the closed Trimmune license for HCW11-006. Quarterly net loss widened to $5.2 million from $1.9 million a year earlier, weighed down by a $2.4 million loss on warrant fair value changes. The company disclosed substantial doubt about its ability to continue as a going concern for at least 12 months without additional funding, with cash and equivalents of just $741,324 at June 30, 2026.
Key figures
- Revenue
- $135,568 for Q2 2026; $6.7 million for the six months ended June 30, 2026
- Total Debt
- 6561361
- Revenue Yoy
- Q2 revenue up from $6,550 in Q2 2025; six-month revenue up from $11,615 in H1 2025
- Total Assets
- 26768318
- Cash Position
- 741324
- Car t market 2025
- $4.0 billion
- Ga expense q2 2026
- 1870375
- Rd expense q2 2026
- 1203352
- Reverse split ratio
- 1-for-6
- Investments jun 30 2026
- 4854028
- Total equity financings
- 5600000
- Shares issued jun 30 2026
- 1617642
- Weighted avg shares q2 2026
- 1327966
- Accounts payable jun 30 2026
- 10609950
- Car t market 2032 projection
- $15.0 billion
- Stockholders equity jun 30 2026
- 7427614
- Gain on extinguishment of liability
- 483383
- July 2026 private placement proceeds
- 1600000
- May 2026 private placement gross proceeds
- 4000000
Price after filing
Close on the filing date to close N calendar days later (from $2.68). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.